Kenvue Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Kenvue (NYSE:KVUE) has received mixed analyst ratings in the last quarter with 1 bullish, 1 somewhat bullish, and 2 indifferent. The average 12-month price target among 4 analysts is $23.75, with a high of $26.00 and a low of $20.00. The current average target has declined by 8.65% from the previous $26.00. Analysts from UBS, Piper Sandler, Goldman Sachs, and JP Morgan have provided updates, with UBS and Piper Sandler maintaining a neutral stance, while Goldman Sachs and JP Morgan have lowered their targets but still suggest a buy/overweight rating. Kenvue, a spin-off from Johnson & Johnson's consumer segment, went public in May 2023 and is a leader in consumer health with $15 billion in annual revenue. Despite a positive revenue trend and strong financial indicators like net margin and ROE, its revenue growth lags behind industry peers.
December 19, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kenvue has a mixed outlook from analysts with a reduced average price target of $23.75, indicating potential cautiousness among investors. The company's strong financials may provide some support, but the reduced target suggests tempered expectations.
The mixed analyst ratings and the decrease in the average price target could lead to short-term uncertainty in Kenvue's stock price. However, the company's strong financial performance and market position may mitigate negative impacts. The score is neutral due to these counterbalancing factors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100